

September 9, 2024

Intraday						
Action	Sc	rip	Target 1	Target 2 St	toploss	Time frame
Buy NIITEC Sept Fut at 6630.1-6636.1	-6636.1 Coforge			6783.1	6573	Intraday
Sell AARIND Sept Fut at 605.95-608.95	Aarti Indust	ries Limited	598.5	585.0	616	Intraday
Weekly					Dui	<u>y view</u>
X	Scrip	Target	Stoplo	ss Time fram	ne	Status
Buy DIVLAB Sep Fut at 5115.0-5125.0	Divis Lab	5325.0	4990	0 Weekly	carr	ied forward
Sell BATIND Sep Fut at 1412.0-1418.0	Bata India	1330.0	1461	.0 Weekly		open
					Wee	ekly view

Other Product offeringsDerivatives StrategyUnderlyingActionDivis LabBuyDuration : 1-2 monthsClick here to see open callsQuant (Derivatives) PickUnderlyingActionHavellsBuyCUBBuy

Duration : 1-3 months Click here to see <u>open calls</u>

For Instant stock ideas: SUBSCRIBE to mobile notification on ICICIdirect Mobile app...

Research Analysts

Jay Thakkar jay.thakkar@icicisecurities.com

Dipesh Dedhia

dipesh.dedhia@icicisecurities.com

Raj Deepak Singh rajdeepak.singh@icicisecurities.com

Siddhesh Jain siddhesh.jain@icicisecurities.com

Picici direct Research

Weekly future recommendations:

1) Buy DIVLAB (DIVIS LAB) SEP in the range of 5115-5125 Target 5325 and StopLoss 4990.(carried forward) Rationale

In recent weeks, Divis Lab has consolidated within the 4900 to 5100 range, with notable delivery buying at these levels indicating accumulation in the stock. Given its moderate leverage, we believe the stock is poised for fresh buying, which could drive it higher from current levels. On the options front, the 5100 Call strike has significant open interest, which had been acting as a resistance. However, last week, the September futures managed to break above this level. We expect the stock to maintain its upward momentum, supported by short covering in call writers' positions, potentially leading it towards the 5325 level.

2) Sell BATIND (BATA INDIA LIMITED) SEP in the range of 1412-1418 Target 1330 and StopLoss 1461.

<u>Rationale</u>

Bata India has once again reversed from its resistance level of 1480. The current decline is accompanied by an increase in open interest in the futures segment, suggesting the addition of short positions. On the options front, the 1480 and 1500 call strikes are showing significant open interest, indicating limited upside potential. The overall price setup appears weak, suggesting that this weakness could extend further down towards 1330 levels.

Recommendation follow up								
Underlying	View	Strategy	Reco	Target		Profit/Loss	Comment	
Astral	Bearish	Sell Futures	1941	1835	2000	11010	Profits Booked	

Source: Bloomberg, ICICI Direct Research


The recommendation was released on One click derivatives on

Nifty: Range shifts lower to 24500 and 25000...

September 9, 2024




- Nifty broke its four-week winning streak, closing with losses exceeding 1.5%. The most significant decline was in the CPSE index, ٠ where PSU banks faced sharp corrections, losing nearly 4%. However, despite global volatility, the broader market continued to outperform.
- Looking ahead, we anticipate that 25300 will serve as an immediate resistance level. Aggressive long positions should be avoided ٠ unless Nifty sustains above 25000 levels. In the options segment, notable Call writing is evident at both ATM and OTM strikes, signaling selling pressure at higher levels. Meanwhile, the primary Put base for the upcoming week is seen at the OTM 24500 strike. Interestingly, more Put closures were observed for the monthly expiry rather than the weekly expiry which suggests weakness likely to continue.
- In futures segment, Nifty index leverages remains high, apart of FIIs other market participant holds short positions. Additionally, the ٠ high premium (basis) in Nifty futures suggests that upward movements could be limited in the coming week. Therefore, a sustainable move above 25000 is crucial to signal the start of a fresh uptrend on the back short covering among call writers positions.
- The VIX closed the week 11% higher, following a sharp reversal after hitting an all-time high of 25300. Put closures at the monthly series of 25000 strike contributed to the market pullback, and VIX has been on the rise. We anticipate that this increase in volatility could extend in the near term.



Bank Nifty: Immediate support placed at 50000...



- The banking index significantly underperformed the broader market last week, losing almost 1.75%. Bank Nifty closed below the 51000 mark, and a major recovery seems unlikely unless it surpasses 51500 during the current settlement.
- In the options segment, Call strikes at 51000 and 51500 hold significant open interest, indicating resistance. On the Put side, there
 is no substantial concentration, with the highest Put base at 50000, which is likely to act as immediate support. A move above
 51500 could trigger short covering and extend the uptrend in Bank Nifty.
- Stock-specific performance was weak, with both private and public sector banks underperforming despite broader market strength. HDFC Bank provided some support by closing flat, but overall, Bank Nifty's relative underperformance is expected to continue, with a potential down move toward 50000 levels.
- In Financial Nifty, the index failed to cross the 24000 mark, and profit-taking in the NBFC space led to a sharp reversal. As with Bank Nifty, Call writers are heavily active in Financial Nifty, suggesting further downside potential. We expect this profit-taking phase to extend toward the 23,200 and 23,000 levels in coming week.



September 9, 2024 Source: Bloomberg, ICICI Direct Research ICICI Securities Ltd. | Retail Equity Research

Fll's turned net buyer...



- Globally, the S&P 500 Index experienced its steepest weekly decline in 15 months, as concerns about a potential economic slowdown seemed to dampen market participant sentiment. US Treasury yields across curve nose dive after weaker than expected economic data from US cemented hopes for rate cut in September meeting however there is no clear signs on size of rate cut
- Domestically, FII's buying spree continued and remained net buyer for the second consecutive week despite some selling were seen in the last two trading sessions. FII's have bought 7.6k crore vs 24k crore seen in the last week. Also, DII remained net buyer of 7.5k crore.
- In the F&O space, FIIs have continue to increase their long positions during the week and their net long positions in index future has
 decreased to over 1.6 lakh contracts from 2.1 lakh contracts as markets witnessed profit taking. On the other hand, retail
 participants has covered their short positions in the current pullback, from net short of 91k contract to 17k contract. In the stock
 futures segment, FIIs continue to remained net longs with 5.4 lakh contracts.
- Crude oil prices declined by 7.45% in the previous week amid weaker than expected economic data from US and concern over Chinese demand. Further, prices dip on signals that Libya's rival factions could be closer to an agreement to end the dispute. For this week, we expect NYMEX crude oil prices to bounce back towards \$72 level amid potential hurricane system approached the US Gulf Coast, larger than expected withdrawal from US crude oil inventories and OPEC+ to delay planned oil output increases.

FII/DII buying in equities (in ₹ crore)										
		DII								
Date	Index Fut	Stock Fut	Index Opt	Cash	Cash					
02-Sep-24	-600	2186	-8469	5153	356					
03-Sep-24	389	5992	25247	2968	1896					
04-Sep-24	-1333	-5541	-29081	1197	97					
05-Sep-24	-670	-4201	-58671	-1047	2971					
06-Sep-24	-3107	-7266	1264	-621	2121					

Source: Bloomberg, ICICI Direct Research

Intraday recommendation with historical price performance...



i) Coforge (CMP: 6633.1) ii) Aarti Industries Limited (CMP: 607.45) Buy NIITEC Sept Fut at | 6630.1-6636.1 Sell AARIND Sept Fut at | 605.95-608.95 Target 1: 6693.1 Target 2: 6783.1 Target 1: 598.5 Target 2: 585 Stop Loss: 6573.1 Stop Loss: 616.5 2150 7100 1950 6100 1750 5100 1550 4100 1350 3100 1150 2100 950 1100 750 30-Jun-23 29-Aug-22 29-0ct-22 31-Aug-23 29-Dec-22 28-Feb-23 30-Apr-23 31-0ct-23 29-Feb-24 31-Dec-23 100 30-Jun-23 31-Oct-23 28-Feb-23 29-Aug-22 29-0ct-22 29-Dec-22 31-Aug-23 31-Dec-23 30-Jun-24 30-Apr-23 29-Feb-24 30-Apr-24

Strategy Follow-up									
Date	Stock	View	Strategy	Reco	Target	SL	P&L	Comment	
6-Sep-24	RAMCEM	Buy	Long Fut	850.5	861.0	839.9	-9010	Stoploss Triggered	
6-Sep-24	ABB	Sell	Short Fut	7668.7	7596.7	7740.7	-	Not initiated	

Source: NSE, Seediff, Bloomberg ICICI Direct Research


September 9, 2024

30-Jun-24

30-Apr-24

Recommended Stocks: Historical price performance...







Source: NSE, Seediff, Bloomberg ICICI Direct Research

September 9, 2024

ICICI Securities Ltd. | Retail Equity Research

Forthcoming Events...



Date & Time (IST)	Country	Data & Events
Monday, September 9, 2024		
7:00 AM	China	CPI y/y
2:00 PM	Europe	Sentix Investor Confidence
Tuesday, September 10, 2024		
11:30 AM	UK	Claimant Count Change
11:30 AM	UK	Average Earnings Index 3m/y
Wednesday, September 11, 2024		
11:30 AM	UK	GDP m/m
6:00 PM	US	СРІ у/у
8:00 PM	US	Crude Oil Inventories
Thursday, September 12, 2024		
5:30 PM	India	CPI y/y
5:45 PM	Europe	Main Refinancing Rate
6:00 PM	US	PPI m/m
6:00 PM	US	Unemployment Claims
8:00 PM	US	Natural Gas Storage
Friday, September 13, 2024		
2:30 PM	Europe	Industrial Production m/m
7:30 PM	US	Prelim UoM Consumer Sentiment
7:30 PM	US	Prelim UoM Inflation Expectations

September 9, 2024 Source: Bloomberg, ICICI Direct Research ICICI Securities Ltd. | Retail Equity Research

8

Derivatives Strategies: Open recommendations



Date	Scrip	Action	Recommendation
2-Sep-24	Divis Laboratories	Buy	Positional Future : Buy Divis Lab SEP in the range of 5115-5125 Target 5325 and StopLoss 4990
5-Sep-24	Apollo Hospital	Buy	Long/Short Strategy: Buy Apollo hospital 6980- 7020, Sell 7300 Call 64-67, Target 7300, Stoploss 6789., Till Expiry.
5-Sep-24	PVR	Buy	Long/Short Strategy: Buy PVR INOX Sept futures 1570-1579, Sell 1660 16-18, Target 1660, Stoploss 1504.9, Till expiry
6-Sep-24	Bata India	Sell	Positional Future : Sell BATIND (BATA INDIA LIMITED) SEP in the range of 1412-1418 Target 1330 and StopLoss 1461.

Back

Quant Picks: Open recommendations...



Date	Scrip	Action	Price	Target	Stop Loss	Last close	Return (%)	Time
12 Jun 24	Tata Chemical	Buy	1100-1120	1265	1016	1059	-5.4%	3 months
25 Jun 24	City Union Bank	Buy	164-168	190	151	167	-0.6%	3 months
19 Aug 24	Havells	Buy	1865-1885	2165	1710	1872	-0.7%	3 months
22 Aug 24	Bandhan Bank	Buy	202-208	240	185	197	-5.3%	3 months
26 Aug 24	Vedanta Ltd	Buy	450-460	529	418	460	0.0%	3 months
5 Sep 24	SRF	Buy	2600-2630	2960	2400	2504	-4.2%	3 months



Pankaj Pandey Head – Research pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, Third Floor, Brillanto House, Road No 13, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com



Source: Bloomberg, ICICI Direct Research

September 9, 2024

Disclaimer



I/We, , Jay Thakkar MBA (Finance), CMT, Raj Deepak Singh BE, MBA (Finance), Dipesh Dedhia BCOM, MBA (Finance), Siddhesh Jain, BFM, MBA (Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Bhavesh Soni Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular securities not and/or ICICI Securities where ICICI Securities from doing so. Non-rated supplicable regulations and/or ICICI Securities, in circumstances where ICICI Securities from doing so. Non-rated supplicable regulations and/or ICICI Securities indicate the rating in a advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report constitutes investment, legal, accounting and tax advice or a representation that any investment objectives, financial positions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

IGICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Disclaimer



Since associates of ICICI Securities and ICICI Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.